Cannabis Countdown: Top 10 Marijuana And Psychedelic Stock News Stories Of The Week

Welcome to the Cannabis Countdown, the Marijuana Industry’s Number One Curated Weekly News Recap.

In This Week’s Edition, We Recap and Countdown the Top 10 Cannabis and Psychedelic Stock News Stories for the Week of March 22nd – 28th, 2021.

Without further ado, let’s get started.

Yahoo Finance readers, please click here to view the full article.

10. Switch From Robinhood to These Online Brokerages to Invest in Soaring U.S. Cannabis Stocks

At the Height of the Reddit-Fueled GameStop Frenzy, Online Brokerage Robinhood Halted and Then Limited the Buying of GameStop Shares Allegedly to Protect the Interests of Large Hedge Funds Betting Against GME

After the air went out of the GameStop (NYSE: GME) rally, many Robinhood users were furious, while others turned their attention to a limited number of Pot Stocks available to trade on the app. Canadian Licensed Producers (LPs) such as Aphria (NYSE: APHA), Tilray (NASDAQ: TLRY) and Sundial Growers (NASDAQ: SNDL) saw a huge spike in Robinhood trading volume, despite the real action being in the U.S. Cannabis Boom. Top U.S. MSOs like Curaleaf (OTCQX: CURLF), Trulieve (OTCQX: TCNNF) and surging newcomer Red White & Bloom (OTCQX: RWBYF) are unavailable (and largely unknown) to Robinhood investors. With U.S. continuing to gain momentum, ex Robinhood investors looking to invest in U.S. Cannabis Stocks, such as RWBCURA and TRUL, should have a look at these online brokerages.

READ FULL POT STOCKS BROKERS ARTICLE

9. Creso Pharma Receives Commitments Totalling $18 Million

The Financing Was Heavily Oversubscribed and Strongly Supported By a Range of Leading Australian and International Institutions

Creso Pharma (OTC: COPHF) announced that it has secured firm commitments from institutional, professional and sophisticated investors to raise up to A$18 million (before costs) through the issue of approximately 94.7 million new fully paid ordinary shares at an issue price of $0.19 per share. Funds from the raise are expected to be deployed to undertake psychedelic clinical trials upon completion of the Halucenex psychedelics acquisition, advance sales of nutraceutical products globally and increase marketing of cannabis products through Canada.

READ FULL CRESO PHARMA ARTICLE

8. Champignon Brands Files New CSE Listing Statement

Champignon Also Announced it Has Filed an Application With the BCSC and OSC to Revoke Their Cease Trade Orders

Champignon …

Full story available on Benzinga.com

More Cannabis Countdown: Top 10 Marijuana And Psychedelic Stock News Stories Of The Week